Exploring the use of tyrosine kinase inhibitors in glioblastoma and RET-rearranged lung cancer to curtail cell migration and invasion and improve therapy by understanding drug resistance
The exponential increase in targeted tyrosine kinase inhibitor (TKI) therapies approved for use in cancer or in late-stage clinical trials has revolutionized the treatment of solid tumors over the last decade. However, many questions regarding the fundamental biology of oncogenic and wild-type receptor tyrosine kinases (RTKs) and how cancer cells adapt to become resistant to TKI therapies have been raised. This work addresses some of these questions specifically as they relate to glioblastoma (GBM) and RET fusion positive lung adenocarcinoma (LAC). First, I demonstrate the feasibility of targeting ...
(For more, see "View full record.")